Full Press Release Details
Aytu BioScience Announces Hiring of Matthew Phillips as Executive
Vice President of Commercial Operations
CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc.
(NASDAQ: AYTU), a specialty pharmaceutical company focused on
global commercialization of novel products addressing significant
medical needs, today announced the hiring of Matthew Phillips as
the company's Executive Vice President of Commercial
Operations. Mr. Phillips' hiring became effective November 8,
2019 following the recently announced acquisition of a portfolio of
six prescription products from Cerecor, Inc. (the Commercial
Portfolio ) and the accompanying commercial team supporting
the products' growth. Mr. Phillips was responsible for
leading the growth of the Commercial Portfolio as the Chief
Commercial Officer at Cerecor, Inc. and its predecessor company
Zylera Pharmaceuticals.
role as Executive Vice President, Mr. Phillips will lead Aytu
BioScience's commercial operations, inclusive of sales,
national accounts, trade management, specialty distribution, supply
chain and commercial logistics. He will report to Josh Disbrow,
Aytu's Chairman and Chief Executive Officer.
Disbrow commented, I'm very pleased to welcome Matt to
the leadership team at Aytu BioScience. As we expand the product
portfolio and operationalize the newly expanded commercial team,
Matt's continuing leadership in this important role will
enable us to build on the sales momentum he and his team have
generated at Cerecor while also building on the growth the Aytu
products. Matt is a highly-respected, seasoned pharmaceutical
executive with great breadth of experience across all aspects of
commercial operations, and he is the ideal commercial leader for
Aytu during this time of rapid growth.
V. Phillips is business leader and commercial executive who has
held progressive leadership positions at numerous healthcare
companies over his twenty-five-plus year career. Most recently,
Matt served as the Chief Commercial Officer of Cerecor, Inc.
(NASDAQ: CERC), where he led all aspects of commercial operations
and built a profitable pediatric commercial business unit. In
Matt's leadership role at Cerecor, he reported to the Chief
Executive Officer and Board of Directors and had responsibilities
beyond leading the commercial team. These responsibilities included
business development, collaboration with research and development,
leading product and company acquisition processes, and leading
market development in preparation for the commercialization of
multiple orphan drug candidates.
to Cerecor, Matt was the President and Chief Operating Officer of
Zylera Pharmaceuticals, which was acquired by Cerecor in 2017. Matt
ran all aspects of commercial operations at Zylera and built a
high-performing, entrepreneurial commercial organization that
experienced rapid growth during his tenure. Previous to joining
Zylera, Matt served as Executive Director of Managed Markets and
Corporate Accounts at Victory Pharmaceuticals, where he developed
and oversaw all aspects of reimbursement, distribution, and
government accounts.
in his pharmaceutical career, Matt was an integral member of the
management teams at Dura Pharmaceuticals and Eisai, Inc. Matt began
his career in the home health care industry where he held
progressive positions in sales and sales management.
earned his bachelor's degree in Business from Central
Michigan University, completed the University of Michigan Executive
Education Leadership Development Program and currently maintains an
appointed position on the North Carolina Board of Science,
Technology and Innovation.
About Aytu BioScience, Inc.
BioScience is a commercial-stage specialty pharmaceutical company
focused on commercializing novel products that address significant
patient needs. The company currently markets Natesto , the
only FDA-approved nasal formulation of testosterone for men with
hypogonadism (low testosterone, or "Low T"). Aytu also has
exclusive U.S. and Canadian rights to ZolpiMist , an
FDA-approved, commercial-stage prescription sleep aid indicated for
the short-term treatment of insomnia characterized by difficulties
with sleep initiation. Aytu is the exclusive U.S. licensee with
commercial rights to Tuzistra XR, the only FDA-approved
12-hour codeine-based antitussive syrup. Tuzistra XR is a
prescription antitussive consisting of codeine polistirex and
chlorpheniramine polistirex in an extended-release oral suspension.
Additionally, Aytu is developing MiOXSYS , a novel, rapid
semen analysis system with the potential to become a standard of
care for the diagnosis and management of male infertility caused by
oxidative stress. MiOXSYS is commercialized outside of the U.S.
where it is a CE Marked, Health Canada cleared, Australian TGA
approved, Mexican COFEPRAS approved product, and Aytu is planning
U.S.-based clinical trials in pursuit of 510k de novo medical
device clearance by the FDA. Aytu's strategy is to continue
building its portfolio of revenue-generating products, leveraging
its focused commercial team and expertise to build leading brands
within large therapeutic markets. For more information visit
Forward-Looking Statements
press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, or the
Exchange Act. All statements other than statements of historical
facts contained in this presentation, are forward-looking
statements. Forward-looking statements are generally written in the
future tense and/or are preceded by words such as ''may,''
''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,''
''suggest,'' ''believe,'' ''estimate,'' ''continue,''
''anticipate,'' ''intend,'' ''plan,'' or similar words, or the
negatives of such terms or other variations on such terms or
comparable terminology. These statements are just predictions and
are subject to risks and uncertainties that could cause the actual